Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.

ABSTRACT:

Purpose

Pathologic response assessment of tumor specimens from patients receiving systemic treatment provides an early indication of therapeutic efficacy and predicts long-term survival. Grading systems for pathologic response were first developed for chemotherapy in select tumor types. Immunotherapeutic agents have a mechanism of action distinct from chemotherapy and are being used across a broad array of tumor types. A standardized, universal scoring system for pathologic response that encompasses features characteristic for immunotherapy and spans tumor types is needed.

Experimental design

Hematoxylin and eosin-stained slides from neoadjuvant surgical resections and on-treatment biopsies were assessed for features of immune-related pathologic response (irPR). A total of 2

SUBMITTER: Stein JE 

PROVIDER: S-EPMC7002263 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature